Epstein Barr Virus Latency

描述（由申请人提供）：非角化性鼻咽癌（NPC）100%与致癌人类疱疹病毒EB病毒相关。它分为两个亚型：低分化（II型）和未分化（III型）。III型是迄今为止最常见的疾病形式。虽然NPC是一个主要的世界健康问题，但它仍然没有得到充分的研究。此外，由于它发生在一个隐匿的部位，最初表现为上呼吸道感染相关的症状，它往往直到晚期才被发现。这是至关重要的，因为早期疾病是容易治疗和潜在可治愈的，而晚期疾病的治疗导致高发病率和复发率，并且没有治疗转移性疾病的有效选择。因此，迫切需要开发针对晚期疾病的新疗法。在这项研究中，我们正在使用系统生物学技术来识别有助于NPC肿瘤生长和转移的候选分子和过程。其目的是研究潜在的机制，也可以确定新疗法的目标。在这项工作中，在体外和体内（小鼠）模型的NPC肿瘤的生长和转移将开发。在体外，将使用培养的原代上皮细胞、充分表征的NPC细胞系和直接从NPC活检中培养的肿瘤细胞。体内异位肿瘤生长和新开发的原位NPC转移模型将使用异种移植的NPC细胞系和肿瘤活检样品。这些模型将允许评估在初步研究中已经确定的过程如何有助于疾病的发展和进展。这些是：1.基于III型NPC中PI 3激酶/Akt/mTOR信号通路的优先失调，验证II型和III型NPC在分子遗传水平上不同的想法。这种失调是否会使III型肿瘤更容易受到靶向该途径的药物的影响，以及这些药物是否会阻碍肿瘤在体内的侵袭和转移行为。 2.探讨趋化因子CCL 5（RANTES）在上皮细胞和鼻咽癌细胞迁移、侵袭和转移中的作用。 3.研究EBV编码的潜伏蛋白LMP 1和LMP 2a在体内肿瘤生长和转移中的作用，激活PI 3 linase/Akt/mTOR信号通路，诱导RANTES依赖的迁移、侵袭和转移。 4.建立EBV相关肿瘤中EBV miRNA表达的定量分析，特别是NPC。将聚类算法应用于这些数据集，以定义在NPC中表达上调或下调的miRNA，以鉴定其靶基因，并最终评估这些基因在体内肿瘤生长和转移中的作用。

DESCRIPTION (provided by applicant): Non-keratinizing nasopharyngeal carcinoma (NPC) is 100% associated with the presence of the oncogenic human herpesvirus Epstein-Barr virus. It is divided into two sub types: poorly differentiated (type II) and undifferentiated (type III). Type III is by far the most common form of the disease. Although a major world heath problem, NPC remains understudied. Furthermore, because it develops in an occult site and initially presents with symptoms associated with upper respiratory tract infection, it often remains undetected until it has reached an advanced stage. This is critical because early stage disease is readily treatable and potentially curable, whereas therapeutics for advanced stage disease result in high morbidity and relapse rates and there are no effective options for treating metastatic disease. Therefore there is a pressing need for the development of new therapies that target advanced disease. In this study we are using systems biology techniques to identify candidate molecules and processes that contribute to NPC tumor growth and metastasis. The intent is to investigate underlying mechanisms that may also identify targets for new therapies. In this work in vitro and in vivo (mouse) models of NPC tumor growth and metastasis will be developed. In vitro, cultured primary epithelial cells, well characterized NPC cell lines and tumor cells cultured directly from NPC biopsies will be used. In vivo ectopic tumor growth and a newly developed orthotopic NPC metastasis model will be used employing xenotransplanted NPC cell lines and tumor biopsy samples. These models will allow the evaluation of how processes, already identified in preliminary studies, contribute to disease development and progression. These are: 1. to test the idea that type II and type III NPC are distinct at the molecular genetic level based on preferential deregulation of the PI3kinase/Akt/mTOR signaling pathway in type III NPC. Does this deregulation make type III tumors more vulnerable to drugs that target this pathway and will such drugs impede the invasive and metastatic behavior of the tumors in vivo. 2. To study the role of the chemokine CCL5 (RANTES) in mediating epithelial and NPC tumor cell migration, invasion and metastasis. 3. Study the role of the EBV encoded latent proteins LMP1 and LMP2a in tumor growth and metastasis in vivo, activation of the PI3linase/Akt/mTOR signaling pathway and induction of RANTES dependent migration, invasion and metastasis. 4. To develop quantitative profiles of EBV miRNA expression in EBV associated tumors with special emphasis on NPC. Apply clustering algorithms to these data sets to define miRNAs whose expression is up- or down-regulated in NPC in order to identify their target genes and ultimately assess the role of these genes in tumor growth and metastasis in vivo.